DOSE-RANGING STUDY OF ONCE-DAILY MIRABEGRON (YM178), A NOVEL SELECTIVE β3-ADRENOCEPTOR AGONIST, IN PATIENTS WITH OVERACTIVE BLADDER (OAB)

被引：37

作者：

Chapple, C. ^{[1
]}

Wyndaele, J. J. ^{[2
]}

Van Kerrebroeck, P. ^{[3
]}

Radziszewski, P. ^{[4
]}

Dvorak, V. ^{[5
]}

Boerrigter, P. ^{[6
]}

机构：

[1] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England

[2] Univ Antwerp, Fac Med, B-2020 Antwerp, Belgium

[3] Univ Med Ctr Maastricht, Maastricht, Netherlands

[4] Med Univ Warsaw, Dept Urol, Warsaw, Poland

[5] Private Obstet Gynecol Clin, Brno, Czech Republic

[6] Astellas Pharma, Med & Clin Dev, Global Dev EU, Leiderdorp, Netherlands

来源：

EUROPEAN UROLOGY SUPPLEMENTS | 2010年 / 9卷 / 02期

关键词：

D O I：

10.1016/S1569-9056(10)60758-0

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：249 / 249

页数：1

共 50 条

[21] Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study
Yamaguchi, Osamu
Marui, Eiji
Igawa, Yasuhiko
Takeda, Masayuki
Nishizawa, Osamu
Ikeda, Yasushi
Ohkawa, Sumito
LUTS-LOWER URINARY TRACT SYMPTOMS, 2015, 7 (02) : 84 - 92
[22] DOSE-RANGING STUDY OF A NEW, ONCE-DAILY DILTIAZEM FORMULATION FOR PATIENTS WITH STABLE ANGINA
CUTLER, NR
EFF, J
FROMELL, G
BRASS, EP
ARCHER, S
CHRYSANT, SG
FIDDES, R
JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 35 (02): : 189 - 195
[23] Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB)
Rossanese, Marta
Novara, Giacomo
Challacombe, Ben
Iannetti, Alessandro
Dasgupta, Prokar
Ficarra, Vincenzo
BJU INTERNATIONAL, 2015, 115 (01) : 32 - 40
[24] Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder:: results of a fixed dose study
Hill, S
Khullar, V
Wyndaele, JJ
Lheritier, K
INTERNATIONAL UROGYNECOLOGY JOURNAL, 2006, 17 (03) : 239 - 247
[25] Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study
Simon Hill
Vik Khullar
Jean-Jacques Wyndaele
Karine Lheritier
International Urogynecology Journal, 2006, 17 : 239 - 247
[26] EFFICACY OF ONCE-DAILY VIBEGRON 75 MG FOR OVERACTIVE BLADDER (OAB) IN OLDER PATIENTS: THE EMPOWUR RANDOMIZED, INTERNATIONAL, PHASE 3 STUDY
Frankel, Jeffrey
Staskin, David
Varano, Susann
Shortino, Denise
Jankowich, Rachael
Mudd, Paul N.
JOURNAL OF UROLOGY, 2020, 203 : E453 - E454
[27] Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective 3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
Kobayashi, Minoru
Nukui, Akinori
Kamai, Takao
LUTS-LOWER URINARY TRACT SYMPTOMS, 2018, 10 (02) : 158 - 166
[28] Efficacy and Tolerability of Mirabegron, a β3-Adrenoceptor Agonist, in Patients with Overactive Bladder: Results from a Randomised European-Australian Phase 3 Trial
Khullar, Vik
Amarenco, Gerard
Angulo, Javier C.
Cambronero, Javier
Hoye, Kjetil
Milsom, Ian
Radziszewski, Piotr
Rechberger, Tomasz
Boerrigter, Peter
Drogendijk, Ted
Wooning, Marianne
Chapple, Christopher
EUROPEAN UROLOGY, 2013, 63 (02) : 283 - 295
[29] Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β3-Adrenoceptor Agonist, in Japanese Patients with Overactive Bladder
Yamaguchi, Osamu
Ikeda, Yasushi
Ohkawa, Sumito
LUTS-LOWER URINARY TRACT SYMPTOMS, 2017, 9 (01) : 38 - 45
[30] Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective β3-adrenoceptor agonist, on bladder function
Takasu, Toshiyuki
Ukai, Masashi
Sato, Shuichi
Matsui, Tetsuo
Nagase, Itsuro
Maruyama, Tatsuya
Sasamata, Masao
Miyata, Keiji
Uchida, Hisashi
Yamaguchi, Osamu
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2007, 321 (02): : 642 - 647

← 1 2 3 4 5 →